12:00 AM
May 18, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Antisoma, sanofi-aventis sales and marketing update

sanofi-aventis acquired exclusive, U.S. rights to Oforta fludarabine from Antisoma for $60 million in cash up front plus $5 million over five years. The oral purine nucleoside analog was approved last December in the U.S. as second-line therapy to treat B cell chronic lymphocytic leukemia (B CLL).

Antisoma gained the product...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >